BMC128 + nivolumab

BMC128 + nivolumab is an investigational combination therapy consisting of BMC128, a rationally designed live bacterial consortium (live biotherapeutic product), and nivolumab, a monoclonal antibody immune checkpoint inhibitor targeting PD-1. BMC128 comprises four specific bacterial strains intended to modulate the gut microbiome and enhance anti-tumor immune responses. Nivolumab is an approved anti-PD-1 monoclonal antibody that blocks the programmed death-1 receptor on T cells to restore anti-tumor immunity. The combination is being developed for use in patients with refractory solid tumors—including clear cell renal cell carcinoma (ccRCC), non-small cell lung cancer (NSCLC), and cutaneous melanoma—who have progressed on prior PD-1/PD-L1 inhibitor therapies. Preliminary phase 1 clinical data show manageable safety and encouraging clinical activity in these populations[2][5][6].

Brand names

Opdivo (for nivolumab)